Immunotherapy for cardiovascular disease

Elisa Martini, Giuliano Giuseppe Stirparo, Marinos Kallikourdis

Research output: Contribution to journalReview articlepeer-review


Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.

Original languageEnglish
JournalJournal of Leukocyte Biology
Publication statusE-pub ahead of print - Dec 19 2017


  • Journal Article
  • Review


Dive into the research topics of 'Immunotherapy for cardiovascular disease'. Together they form a unique fingerprint.

Cite this